A Randomized, Multicenter, International, Open-Label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MT naïve Subjects With Active Psoriatic Arthritis.

Trial Profile

A Randomized, Multicenter, International, Open-Label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MT naïve Subjects With Active Psoriatic Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Infliximab (Primary) ; Methotrexate
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms RESPOND
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 12 Oct 2011 Results published in full in the Annals of the Rheumatic Diseases.
    • 21 Oct 2009 Results presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology.
    • 17 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top